Susan Knox
Publications
- Characterization of direct radiation-induced immune function and molecular signaling changes in an antigen presenting cell line. Clin Immunol. 2013; (1): 44-55
- A systemic complete response of metastatic melanoma to local radiation and immunotherapy. Transl Oncol. 2012; (6): 404-7
- Abscopal effect in a patient with melanoma. N Engl J Med. 2012; (21): 2035; author reply 2035-6
- Beyond antiangiogenesis: vascular modulation as an anticancer therapy-a review. Transl Oncol. 2012; (3): 133-40
- Darinaparsin: solid tumor hypoxic cytotoxin and radiosensitizer. Clin Cancer Res. 2012; (12): 3366-76
- Dinitroazetidines are a novel class of anticancer agents and hypoxia-activated radiation sensitizers developed from highly energetic materials. Cancer Res. 2012; (10): 2600-8
- Is Nitric Oxide (NO) the Last Word in Radiosensitization? A Review. Transl Oncol. 2012; (2): 66-71
- Mitigation of radiation-induced dermatitis by activation of aldehyde dehydrogenase 2 using topical alda-1 in mice. Radiat Res. 2012; (1): 69-74
- The scarlet letter of alkylation: a mini review of selective alkylating agents. Transl Oncol. 2012; (4): 226-9
- Six degrees of separation: the oxygen effect in the development of radiosensitizers. Transl Oncol. 2011; (4): 189-98
- 131I-Tositumomab (Bexxar) vs. 90Y-Ibritumomab (Zevalin) therapy of low-grade refractory/relapsed non-Hodgkin lymphoma. Mol Imaging Biol. 2010; (2): 198-203
- Anti-alphav integrin monoclonal antibody intetumumab enhances the efficacy of radiation therapy and reduces metastasis of human cancer xenografts in nude rats. Cancer Res. 2010; (19): 7591-9
- Anti-tumor and radiosensitization activities of the iron chelator HDp44mT are mediated by effects on intracellular redox status. Cancer Lett. 2010; (2): 231-7
- Impact of rituximab treatment on (90)Y-ibritumomab dosimetry for patients with non-Hodgkin lymphoma. J Nucl Med. 2010; (1): 150-7
- In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study. J Clin Oncol. 2010; (28): 4324-32
- Metalloporphyrin synergizes with ascorbic acid to inhibit cancer cell growth through fenton chemistry. Cancer Biother Radiopharm. 2010; (4): 439-48
- Sodium selenite radiosensitizes hormone-refractory prostate cancer xenograft tumors but not intestinal crypt cells in vivo. Int J Radiat Oncol Biol Phys. 2010; (1): 230-6
- Lanreotide promotes apoptosis and is not radioprotective in GH3 cells. Endocr Relat Cancer. 2009; (3): 1045-55
- Anti-integrin monoclonal antibody CNTO 95 enhances the therapeutic efficacy of fractionated radiation therapy in vivo. Mol Cancer Ther. 2008; (6): 1569-78
- Risks to normal tissues from radionuclide therapy. Semin Nucl Med. 2008; (5): 347-57
- Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. Int J Radiat Oncol Biol Phys. 2008; (3): 935-40
- Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma. Blood. 2007; (11): 4655-62
- Expression and function of erythropoietin receptors in tumors: implications for the use of erythropoiesis-stimulating agents in cancer patients. Cancer. 2007; (3): 477-88
- MIRD continuing education: Bystander and low dose-rate effects: are these relevant to radionuclide therapy? J Nucl Med. 2007; (10): 1683-91
- Targeting integrins and PI3K/Akt-mediated signal transduction pathways enhances radiation-induced anti-angiogenesis. Radiat Res. 2007; (1): 125-33
- Clinical development of radioimmunotherapy for B-cell non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2006; (2 Suppl): S15-22
- Clinical manifestations of noncoronary atherosclerotic vascular disease after moderate dose irradiation. Cancer. 2006; (3): 718-25
- Inhibition of androgen receptor signaling by selenite and methylseleninic acid in prostate cancer cells: two distinct mechanisms of action. Mol Cancer Ther. 2006; (8): 2078-85
- Optimization of combination therapy of arsenic trioxide and fractionated radiotherapy for malignant glioma. Int J Radiat Oncol Biol Phys. 2006; (2): 493-8
- Phase I study of 131I-chimeric(ch) TNT-1/B monoclonal antibody for the treatment of advanced colon cancer. Cancer Biother Radiopharm. 2006; (3): 243-56
- Radiation sensitization with redox modulators: a promising approach. Int J Radiat Oncol Biol Phys. 2006; (2): 343-54
- Tumor-selective killing by selenite in patient-matched pairs of normal and malignant prostate cells. Prostate. 2006; (2): 218-25
- Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005; (12): 4576-82
- Darbepoietin alfa potentiates the efficacy of radiation therapy in mice with corrected or uncorrected anemia. Cancer Res. 2005; (1): 284-90
- Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol. 2005; (31): 7985-93
- Redox modulation of human prostate carcinoma cells by selenite increases radiation-induced cell killing. Free Radic Biol Med. 2005; (1): 50-7
- Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas. J Clin Oncol. 2005; (30): 7565-73
- A novel antiangiogenesis therapy using an integrin antagonist or anti-Flk-1 antibody coated 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys. 2004; (4): 1215-27
- Dosimetry model for radioactivity localized to intestinal mucosa. Cancer Biother Radiopharm. 2004; (3): 293-307
- Enhanced effectiveness of radiochemotherapy with tirapazamine by local application of electric pulses to tumors. Radiat Res. 2004; (2): 185-93
- Enhancement of the efficacy of an antagonist of an extracellular receptor by attachment to the surface of a biocompatible carrier. Pharm Res. 2004; (10): 1880-5
- Increased cure rate of glioblastoma using concurrent therapy with radiotherapy and arsenic trioxide. Int J Radiat Oncol Biol Phys. 2004; (1): 197-203
- Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood. 2004; (1): 227-36
- Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma. Int J Radiat Oncol Biol Phys. 2004; (5): 1274-87
- The radioisotope contributes significantly to the activity of radioimmunotherapy. Clin Cancer Res. 2004; (23): 7792-8
- Distribution of monoclonal antiferritin antibody in Kaposi's sarcoma, Hodgkin's disease, and hepatocellular carcinoma. Hum Pathol. 2003; (4): 381-4
- Radiation-induced cyclooxygenase 2 up-regulation is dependent on redox status in prostate cancer cells. Radiat Res. 2003; (6): 617-21
- Radiobiology of radioimmunotherapy with 90Y ibritumomab tiuxetan (Zevalin). Semin Oncol. 2003; (6 Suppl 17): 6-10
- Role of glutathione depletion and reactive oxygen species generation in apoptotic signaling in a human B lymphoma cell line. Cell Death Differ. 2002; (3): 252-63
- The antiangiogenic agents SU5416 and SU6668 increase the antitumor effects of fractionated irradiation. Radiat Res. 2002; (1): 45-51
- Bcl-2 inhibits apoptosis induced by mitochondrial uncoupling but does not prevent mitochondrial transmembrane depolarization. Exp Cell Res. 2001; (2): 170-9
- Long-term follow-up of patients with Stage III follicular lymphoma treated with primary radiotherapy at Stanford University. Int J Radiat Oncol Biol Phys. 2001; (1): 3-15
- Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2001; (19): 3918-28
- Radioimmunotherapy of B-cell NHL. Curr Pharm Biotechnol. 2001; (4): 327-39
- Rotenone-induced G2/M cell cycle arrest and apoptosis in a human B lymphoma cell line PW. Biochem Biophys Res Commun. 2001; (5): 973-8
- Bcl-2 overexpression results in enhanced capacitative calcium entry and resistance to SKF-96365-induced apoptosis. Cancer Res. 2000; (16): 4358-61
- Clinical radioimmunotherapy. Semin Radiat Oncol. 2000; (2): 73-93
- Introduction Semin Radiat Oncol. 2000; (2): 71-2
- Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin's lymphomas. J Clin Oncol. 2000; (6): 1316-23
- Phase II trial of yttrium-90-DOTA-biotin pretargeted by NR-LU-10 antibody/streptavidin in patients with metastatic colon cancer. Clin Cancer Res. 2000; (2): 406-14
- Radiation induces upregulation of cyclooxygenase-2 (COX-2) protein in PC-3 cells. Int J Radiat Oncol Biol Phys. 2000; (2): 325-8
- G2/M-phase arrest and death by apoptosis of HL60 cells irradiated with exponentially decreasing low-dose-rate gamma radiation. Radiat Res. 1999; (6): 659-69
- Radiation absorbed dose estimation for 90Y-DOTA-biotin with pretargeted NR-LU-10/streptavidin. Cancer Biother Radiopharm. 1999; (5): 381-95
- Radiosensitization by intratumoral administration of cisplatin in a sustained-release drug delivery system. Radiother Oncol. 1999; (2): 215-23
- The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy. Apoptosis. 1999; (2): 115-43
- Direct evidence that apoptosis enhances tumor responses to fractionated radiotherapy. Cancer Res. 1998; (9): 1779-84
- Effects of keratinocyte growth factor on the proliferation and radiation survival of human squamous cell carcinoma cell lines in vitro and in vivo. Int J Radiat Oncol Biol Phys. 1998; (1): 177-87
- Myc activation reduces fibroblast clonogenicity via an apoptotic mechanism that can be suppressed by a soluble paracrine factor. Cancer Lett. 1998; (1-2): 211-9
- p53 mediates apoptosis induced by c-Myc activation in hypoxic or gamma irradiated fibroblasts. Cell Death Differ. 1998; (2): 141-7
- A prospective study of radiation therapy-associated thrombocytopenia. Blood. 1997; (10): 4237-8
- Enhancement of murine intestinal stem cell survival after irradiation by keratinocyte growth factor. Radiat Res. 1997; (3): 248-53
- Influence of Bcl-2 overexpression on Na+/K(+)-ATPase pump activity: correlation with radiation-induced programmed cell death. J Cell Physiol. 1997; (3): 299-304
- Radiobiologic studies of radioimmunotherapy and external beam radiotherapy in vitro and in vivo in human renal cell carcinoma xenografts. Cancer. 1997; (12 Suppl): 2519-28
- Radiotherapy-associated neutropenia and thrombocytopenia: analysis of risk factors and development of a predictive model. Blood. 1997; (7): 2303-10
- Association of BCL-2 with membrane hyperpolarization and radioresistance. J Cell Physiol. 1996; (1): 114-22
- Intratumoral radioimmunotherapy of a human colon cancer xenograft using a sustained-release gel. Radiother Oncol. 1996; (2): 179-89
- Modulation of c-Myc activity and apoptosis in vivo. Cancer Res. 1996; (19): 4315-9
- Over-expression of Bcl-2 protects against apoptosis induced by the bioreductive cytotoxic drug SR4233 (Tirapazamine). Cell Death Differ. 1996; (2): 215-22
- Treatment of cutaneous T-cell lymphoma with chimeric anti-CD4 monoclonal antibody. Blood. 1996; (3): 893-9
- Treatment of hormone-refractory prostate cancer with 90Y-CYT-356 monoclonal antibody. Clin Cancer Res. 1996; (8): 1289-97
- Yttrium-90-labeled anti-CD20 monoclonal antibody therapy of recurrent B-cell lymphoma. Clin Cancer Res. 1996; (3): 457-70
- Effects of stem cell factor on the growth and radiation survival of tumor cells. Cancer Res. 1995; (15): 3431-7
- Multiple courses of high-dose total skin electron beam therapy in the management of mycosis fungoides. Int J Radiat Oncol Biol Phys. 1995; (5): 1445-9
- Overview of studies on experimental radioimmunotherapy. Cancer Res. 1995; (23 Suppl): 5832s-5836s
- Radioimmunotherapy of the Non-Hodgkin's Lymphomas. Semin Radiat Oncol. 1995; (4): 331-341
- Stem cell factor enhances the survival of murine intestinal stem cells after photon irradiation. Radiat Res. 1995; (1): 12-5
- Effect of filgrastim (G-CSF) in Hodgkin's disease patients treated with radiation therapy. Int J Radiat Oncol Biol Phys. 1994; (2): 445-50
- Organ modeling in the quantitation of planar images for distribution studies. Cancer. 1994; (3 Suppl): 919-22
- Stem cell factor enhances the survival of irradiated human bone marrow maintained in SCID mice. Stem Cells. 1994; (4): 430-5
- The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts. Int J Radiat Oncol Biol Phys. 1994; (1): 119-26
- Radiobiology of radiolabeled antibody therapy as applied to tumor dosimetry. Med Phys. 1993 Mar-Apr; (2 Pt 2): 601-10
- Correlation of tumor sensitivity to low-dose-rate irradiation with G2/M-phase block and other radiobiological parameters. Radiat Res. 1993; (1): 24-31
- Determinants of low dose rate effects associated with radioimmunotherapy. Antibody Immunoconjugates and Radiopharmaceuticals. 1993: 197-207
- Local hyperthermia and SR 4233 enhance the antitumor effects of radioimmunotherapy in nude mice with human colonic adenocarcinoma xenografts. Cancer Res. 1993; (13): 3022-7
- Response to letter by A. E. Amin regarding tumour size dependence of relative efficacy of radioimmunotherapy and external beam irradiation in tumour treatment. Radiotherapy Oncology. 1993: 219-220
- The effect of stem cell factor on irradiated human bone marrow. Cancer Res. 1993; (17): 3857-9
- Overview of animal studies comparing radioimmunotherapy with dose equivalent external beam irradiation. Radiother Oncol. 1992; (2): 111-7
- The effect of unlabelled monoclonal antibody (mAb) on the biodistribution of 131I-anti-idiotype mAb in murine B cell lymphoma. Radiother Oncol. 1992; (3): 169-76
- Mycosis fungoides arthropathy. Ann Intern Med. 1991; (7): 571-2
- Observations on the effect of chimeric anti-CD4 monoclonal antibody in patients with mycosis fungoides. Blood. 1991; (1): 20-30
- Results of the 1989 Association of Residents in Radiation Oncology survey. Int J Radiat Oncol Biol Phys. 1991; (6): 1363-7
- The biodistribution of 111In-anti-bFGF in a variety of tumors. Correlation with cell-binding assays. Ann N Y Acad Sci. 1991: 497-502
- Determinants of the antitumor effect of radiolabeled monoclonal antibodies. Cancer Res. 1990; (16): 4935-40
- The changing face of radiation oncology. South Med J. 1990; (4): 488
- Hyperthermia and radiation therapy in the treatment of recurrent Merkel cell tumors. Cancer. 1988; (8): 1479-86
- Effect of thymopoietin and interleukin 2 on depressed mitogenic responsiveness and colony formation of lymphocytes from patients with preleukemia. Thymus. 1986; (1-2): 33-44
- Two independent pathways of helper activity provided by a single T cell clone. J Immunol. 1986; (1): 34-8
- Relation of age to lymphocyte radiosensitivity in vitro. Health Phys. 1984; (2): 431-4
- Lymphocyte abnormalities in preleukemia--I. Decreased NK activity, anomalous immunoregulatory cell subsets and deficient EBV receptors. Leuk Res. 1983; (3): 389-95
- Studies of T-lymphocytes in preleukemic disorders and acute nonlymphocytic leukemia: in vitro radiosensitivity, mitogenic responsiveness, colony formation, and enumeration of lymphocytic subpopulations. Blood. 1983; (3): 449-55
- Assessment of the in vitro radiosensitivity of human peripheral blood lymphocytes. Radiat Res. 1982; (3): 575-89
- Growth of human T lymphocyte colonies from whole blood: culture requirements and applications. J Cell Biochem. 1982; (1): 15-24
- Growth of macrophage colonies from normal canine peripheral blood: morphological, cytochemical and functional parameters. Stem Cells. 1982; (6): 325-44
- Radiation-induced inhibition of human lymphocyte blastogenesis: the effect of superoxide dismutase and catalase. Int J Radiat Biol Relat Stud Phys Chem Med. 1982; (3): 283-94
- Cytogenetics and granulopoietic effects of bone marrow fibroblastic cells in Fanconi's anaemia. Br J Haematol. 1981; (1): 85-93
- Increased radiosensitivity of a subpopulation ot T-lymphocyte progenitors from patients with Fanconi's anemia. Blood. 1981; (6): 1043-8
- The selective growth of human T lymphocyte colonies from whole blood in a semisolid culture system. Exp Hematol. 1981; (9): 926-37
- A "whole-blood" technique for the quantitation of canine "T-lymphocyte" progenitors using a semisolid culture system. Exp Hematol. 1980; (8): 1031-9
- Cell-mediated immunity in the dog in relation to disease: A review. Comp Immun Microbiol Infect Dis. 1980: 405-415
- Susceptibility of clinical isolates of Pseudomonas aeruginosa to antimicrobial agents. Pharmacol Ther. 1979: 275-278
- Pharmacokinetics of penicillin G in the turkey. Am J Vet Res. 1978; (7): 1219-21
Help
Trial Administration